RxDoctor Payments Data

April Phares

Family · Taylorsville, NCNPI 1508410754

Payments from drug & device makers

$8,080in general payments, 2019–2025

Across 466 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Amgen$713
  • AbbVie$685
  • Otsuka America Pharmaceutical, Inc.$610
  • Axsome Therapeutics, Inc.$516
  • Bayer$433
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$8,072100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,080 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$516
Medicare patients
14
Services billed
25

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KrystexxaPegloticase21$592,925
OzempicSemaglutide58$63,069
RexultiBrexpiprazole33$62,485
ZenpepLipase/Protease/Amylase16$53,753
KerendiaFinerenone51$52,713
JardianceEmpagliflozin46$49,465
MounjaroTirzepatide45$46,633
EliquisApixaban27$35,219
FarxigaDapagliflozin Propanediol35$34,443
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$31,659
LinzessLinaclotide23$21,568
VascepaIcosapent Ethyl41$20,737
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog22$17,109
TrulicityDulaglutide16$15,298
Soliqua 100-33Insulin Glargine/Lixisenatide15$13,234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenKrystexxa$713$592,92521 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta$233$66,63573 claims
Novo NordiskOzempic$278$63,06958 claims
Otsuka America Pharmaceutical, Inc.Rexulti$610$62,48533 claims
Lilly USA, LLCMounjaro, Trulicity$381$61,93161 claims
Aimmune Therapeutics, Inc.Zenpep$20$53,75316 claims
BayerKerendia$433$52,71351 claims
PfizerEliquis$358$35,21927 claims
AstraZenecaFarxiga$1,122$34,44335 claims
GSKTrelegy Ellipta$310$31,65935 claims
AbbVieLinzess$685$21,56823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Taylorsville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →